Juniper Investment Company LLC Reduces Stock Holdings in Artivion, Inc. $AORT

Juniper Investment Company LLC lessened its stake in shares of Artivion, Inc. (NYSE:AORT) by 10.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,189,136 shares of the company’s stock after selling 144,556 shares during the period. Artivion comprises about 18.6% of Juniper Investment Company LLC’s portfolio, making the stock its 2nd largest holding. Juniper Investment Company LLC’s holdings in Artivion were worth $54,236,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion in the 3rd quarter worth $27,000. Aster Capital Management DIFC Ltd boosted its position in shares of Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares during the period. Larson Financial Group LLC increased its stake in Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares in the last quarter. USA Financial Formulas lifted its stake in Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock valued at $52,000 after buying an additional 703 shares in the last quarter. Finally, KBC Group NV acquired a new position in shares of Artivion in the fourth quarter worth about $65,000. 86.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

AORT has been the topic of a number of recent analyst reports. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $36.00 price target on shares of Artivion in a report on Tuesday. Weiss Ratings lowered Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Needham & Company LLC decreased their price objective on Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Citizens Jmp lowered their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $44.17.

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the transaction, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This trade represents a 42.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.30% of the company’s stock.

Artivion Stock Down 0.8%

Artivion stock opened at $21.27 on Thursday. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The firm’s fifty day simple moving average is $28.16 and its 200-day simple moving average is $36.44. The company has a market capitalization of $1.03 billion, a P/E ratio of 88.63 and a beta of 1.26.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.